Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL A HASSMAN

Allopathic & Osteopathic Physicians Family Medicine Adult Medicine

NPI
1922002765
CMS profile
223356
Location
BERLIN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,693.85

140 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,693.85 140

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL A HASSMAN

NPI 1922002765 · CMS profile ID 223356

Allopathic & Osteopathic Physicians / Family Medicine / Adult Medicine

BERLIN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922002765?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL A HASSMAN, NPI 1922002765, CMS profile ID 223356. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922002765?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MICHAEL A HASSMAN, NPI 1922002765, CMS profile ID 223356. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922002765?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MICHAEL A HASSMAN, NPI 1922002765, CMS profile ID 223356, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1922002765?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

140 matching records · $1,693.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 140 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–140 of 140.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Esperion Therapeutics, Inc. $13.2704/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838308467 CMS
Novartis Pharmaceuticals Corporation $13.8604/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812712851 CMS
Novo Nordisk Inc $7.4004/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 856594083 CMS
AbbVie Inc. $14.7104/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794771487 CMS
Amgen Inc. $5.7003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825611439 CMS
Novo Nordisk Inc $1.5503/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 856595673 CMS
GlaxoSmithKline, LLC. $12.4503/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803205207 CMS
AbbVie Inc. $11.5103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794771483 CMS
Amgen Inc. $13.1603/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825611519 CMS
Novo Nordisk Inc $13.2703/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811082295 CMS
Amgen Inc. $10.4003/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825611435 CMS
Novo Nordisk Inc $12.2603/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810969235 CMS
Teva Pharmaceuticals USA, Inc. $14.4403/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839605333 CMS
AbbVie Inc. $13.5903/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794771479 CMS
Amgen Inc. $14.8703/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825611431 CMS
Kowa Pharmaceuticals America, Inc. $12.6003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805486533 CMS
Novartis Pharmaceuticals Corporation $14.6703/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812712849 CMS
AbbVie Inc. $11.2603/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794771475 CMS
AbbVie Inc. $10.9103/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794771471 CMS
Amarin Pharma Inc. $15.0003/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815056393 CMS
Amgen Inc. $14.3002/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825611515 CMS
Amgen Inc. $6.3802/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825611427 CMS
Otsuka America Pharmaceutical, Inc. $14.1202/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834735845 CMS
AbbVie Inc. $8.3602/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794771467 CMS
Esperion Therapeutics, Inc. $14.7402/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838308463 CMS
AbbVie Inc. $12.7902/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794771463 CMS
Amarin Pharma Inc. $14.5902/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815249413 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.2602/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849971965 CMS
Novartis Pharmaceuticals Corporation $14.6702/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812712847 CMS
TOPCON HEALTHCARE SOLUTIONS, INC. $147.4202/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840835033 CMS
Biohaven Pharmaceuticals, Inc. $13.9102/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852513403 CMS
Kowa Pharmaceuticals America, Inc. $12.6102/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805486539 CMS
Amgen Inc. $11.9701/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825611511 CMS
Novo Nordisk Inc $13.5401/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811122241 CMS
Esperion Therapeutics, Inc. $13.6601/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838308459 CMS
Amarin Pharma Inc. $14.5901/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815249415 CMS
AbbVie Inc. $16.4701/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794771459 CMS
Amgen Inc. $13.6401/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825611539 CMS
Novo Nordisk Inc $11.5601/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811161713 CMS
Amarin Pharma Inc. $15.0001/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815249411 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,500.86 115
PY2020 $2,857.73 103
PY2021 $1,693.85 140
PY2022 $1,273.85 110
PY2023 $1,539.30 125
PY2024 $2,931.13 132
PY2025 $1,711.95 112

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,753.48 1
PY2025 Principal investigator $1,940,811.99 103
PY2024 Recipient $13,971.52 3
PY2024 Principal investigator $2,136,484.10 114
PY2023 Recipient $98,875.53 6
PY2023 Principal investigator $3,215,456.87 158
PY2022 Recipient $168,297.08 6
PY2022 Principal investigator $4,738,372.57 174
PY2021 Principal investigator $5,986,233.49 76
PY2020 Recipient $752.80 2
PY2020 Principal investigator $3,488,653.24 94
PY2019 Recipient $4,683.30 2
PY2019 Principal investigator $1,089,707.69 102

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

104 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $151,187.75 12/31/2025 Non-covered Recipient Entity
Hassman Research Institute Marlton Site
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants with Opioid Use Disorder No dispute reported 06/30/2026 1232928818
Principal investigator 1 Merck Sharp & Dohme LLC $848.40 12/31/2025 Non-covered Recipient Entity
Hassman Research Institute Marlton Site
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants with Opioid Use Disorder No dispute reported 06/30/2026 1232928862
Principal investigator 1 PFIZER INC. $100,025.00 12/22/2025 Non-covered Recipient Entity
Hassman Research Institute
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCEWEEKLY MET097 IN ADULTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES MELLITUS VESPER2 No dispute reported 06/30/2026 1228721043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,329.60 12/11/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $776.25 12/11/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 12/04/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.00 12/04/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,780.00 12/04/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,915.00 12/04/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,780.00 11/20/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,640.00 11/20/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/20/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 11/20/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263725
Principal investigator 1 PFIZER INC. $114,699.00 11/17/2025 Non-covered Recipient Entity
Hassman Research Institute
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCEWEEKLY MET097 IN ADULTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES MELLITUS VESPER2 No dispute reported 06/30/2026 1228721045
Principal investigator 1 PFIZER INC. $6,000.00 11/17/2025 Non-covered Recipient Entity
Hassman Research Institute
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCEWEEKLY MET097 IN ADULTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES MELLITUS VESPER2 No dispute reported 06/30/2026 1228721047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,608.07 11/14/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261381
Principal investigator 1 ModernaTX, Inc. $6,481.15 11/05/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) No dispute reported 06/30/2026 1252990066
Principal investigator 1 Eli Lilly and Company $312.77 10/27/2025 Non-covered Recipient Entity
ADVOCARE BERLIN MEDICAL ASSOCIATES
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187875885
Principal investigator 1 PFIZER INC. $3,588.36 10/21/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228743167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36,262.46 10/16/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250609
Principal investigator 1 SANOFI PASTEUR INC. $3,200.00 10/13/2025 Non-covered Recipient Entity
Hassman Research Institute Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226102342
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 09/23/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168530
Principal investigator 1 GlaxoSmithKline, LLC. $20,000.00 09/18/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168128
Principal investigator 1 GlaxoSmithKline, LLC. $95.00 09/18/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $566.36 09/18/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240566
Principal investigator 1 PFIZER INC. $14,911.32 09/16/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228757492
Principal investigator 1 GlaxoSmithKline, LLC. $12,250.00 09/04/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168497
Principal investigator 1 ModernaTX, Inc. $2,200.00 09/03/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) No dispute reported 06/30/2026 1252990064
Principal investigator 1 ModernaTX, Inc. $10,500.00 09/03/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) No dispute reported 06/30/2026 1252990068
Principal investigator 1 ModernaTX, Inc. $35,706.54 09/03/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) No dispute reported 06/30/2026 1252990070
Principal investigator 1 ModernaTX, Inc. $2,250.00 09/03/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) No dispute reported 06/30/2026 1252990072
Principal investigator 1 PFIZER INC. $4,525.52 08/23/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228722458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,589.73 08/21/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229761
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,500.00 08/19/2025 Non-covered Recipient Entity
CENEXEL HRI
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190307933
Principal investigator 1 GlaxoSmithKline, LLC. $9,100.00 08/14/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192112755
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 08/14/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168517
Principal investigator 1 PFIZER INC. $1,629.65 08/14/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228784232
Principal investigator 1 ABBVIE INC. $3,215.60 07/24/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202499714
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 07/24/2025 Non-covered Recipient Entity
CENEXEL HRI BERLIN
A Phase 2a Randomized, Observer-blind, Placebo-controlled, Dosage Optimization, Multi-center Clinical Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Adults 60 to 85 Years of Age No dispute reported 06/30/2026 1185545835
Principal investigator 1 GlaxoSmithKline, LLC. $10,243.50 07/22/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $566.36 07/22/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217815
Principal investigator 1 GlaxoSmithKline, LLC. $7,450.00 07/04/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192112761
Principal investigator 1 GlaxoSmithKline, LLC. $59,737.50 07/04/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168136
Principal investigator 1 ABBVIE INC. $600.00 06/27/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202493583
Principal investigator 1 ABBVIE INC. $405.00 06/27/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202493585
Principal investigator 1 PFIZER INC. $852.97 06/27/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228792262
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 06/24/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168503
Principal investigator 1 GlaxoSmithKline, LLC. $163,323.54 06/24/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,342.24 06/24/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210674
Principal investigator 1 PFIZER INC. $882.97 06/14/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228776262
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 06/05/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168507
Principal investigator 1 PFIZER INC. $1,011.88 05/28/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228772599
Principal investigator 1 GlaxoSmithKline, LLC. $872.00 05/22/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168118
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,287.24 05/22/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190307961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,772.27 05/15/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $900.00 05/15/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,300.00 05/15/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,450.00 05/15/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,880.00 05/15/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $900.00 05/15/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194693
Principal investigator 1 PFIZER INC. $1,264.85 05/14/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228782217
Principal investigator 1 Genentech, Inc. $3,781.00 05/07/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611952
Principal investigator 1 PFIZER INC. $505.94 05/06/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228724132
Principal investigator 1 GlaxoSmithKline, LLC. $20,000.00 05/02/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168512
Recipient Nielsen BioSciences, Inc. $2,753.48 04/30/2025 Covered Recipient Physician CFW-3A No dispute reported 06/30/2026 1215182135
Principal investigator 1 GlaxoSmithKline, LLC. $9,500.00 04/28/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168123
Principal investigator 1 GlaxoSmithKline, LLC. $2,741.00 04/28/2025 Non-covered Recipient Entity
CENEXEL HRI
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192168521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,456.62 04/28/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,114.84 04/01/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 03/19/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,120.00 03/19/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174496
Principal investigator 1 PFIZER INC. $1,185.84 03/14/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228779409
Principal investigator 1 Genentech, Inc. $1,010.00 03/12/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611939
Principal investigator 1 Eli Lilly and Company $9,116.00 03/11/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187882888
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $28,641.45 03/10/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123782
Principal investigator 1 Novartis Pharmaceuticals Corporation $139,768.59 03/07/2025 Non-covered Recipient Entity
CENEXEL HRI
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190307935
Principal investigator 1 Genentech, Inc. $6,811.00 03/05/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,494.60 03/04/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156684
Principal investigator 1 Genentech, Inc. $4,040.00 02/26/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,800.00 02/25/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155430
Principal investigator 1 PFIZER INC. $875.00 02/22/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228771247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $346.95 02/21/2025 Non-covered Recipient Entity
Hassman Research Institute
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519036
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,799.60 02/21/2025 Non-covered Recipient Entity
Hassman Research Institute
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $346.95 02/21/2025 Non-covered Recipient Entity
Hassman Research Institute
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,320.06 02/14/2025 Non-covered Recipient Entity
Hassman Research Institute
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM No dispute reported 06/30/2026 1215519017
Principal investigator 1 PFIZER INC. $897.09 02/14/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228758875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,324.36 02/11/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152984
Principal investigator 1 Alnylam Pharmaceuticals Inc. $346.95 02/03/2025 Non-covered Recipient Entity
Hassman Research Institute
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,040.85 02/03/2025 Non-covered Recipient Entity
Hassman Research Institute
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519060
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
ADVOCARE BERLIN MEDICAL ASSOCIATES
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1187875253
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,605.76 01/30/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190307959
Principal investigator 1 PFIZER INC. $10,323.81 01/30/2025 Non-covered Recipient Entity
Hassman Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228799048
Principal investigator 1 SANOFI PASTEUR INC. $257,602.95 01/21/2025 Non-covered Recipient Entity
Hassman Research Institute Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226102319
Principal investigator 1 Eli Lilly and Company $290,563.00 01/17/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1187883178
Principal investigator 1 SANOFI PASTEUR INC. $2,177.56 01/13/2025 Non-covered Recipient Entity
Hassman Research Institute Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226102312
Principal investigator 1 Alnylam Pharmaceuticals Inc. $32,400.67 01/08/2025 Non-covered Recipient Entity
Hassman Research Institute
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $519.87 01/07/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28,350.00 01/07/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145912
Principal investigator 1 Alnylam Pharmaceuticals Inc. $267.50 01/03/2025 Non-covered Recipient Entity
Hassman Research Institute
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM No dispute reported 06/30/2026 1215519021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $600.00 01/03/2025 Non-covered Recipient Entity
Hassman Research Institute
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM No dispute reported 06/30/2026 1215519025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,250.00 01/03/2025 Non-covered Recipient Entity
Hassman Research Institute
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM No dispute reported 06/30/2026 1215519029
Principal investigator 1 Genentech, Inc. $5,253.00 01/03/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611942
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,606.90 01/01/2025 Non-covered Recipient Entity
CENEXEL HRI
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190307931
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $133,590.43 01/01/2025 Non-covered Recipient Entity
HASSMAN RESEARCH INSTITUTE
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124400